HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

HUTCHMED (China) Limited

Citi analyst maintained a Buy rating on HUTCHMED (China) on September 3 and set a price target of HK$39.00. The company’s shares closed yesterday a...

Citi Sticks to Its Buy Rating for HUTCHMED (China)  (HCM)

HUTCHMED (China) received a Buy rating and a HK$28.50 price target from Daiwa analyst on September 3. The company’s shares closed yesterday at HK$2...

Positive Report for HUTCHMED (China)  (HCM) from Daiwa

The latest announcement is out from Hitachi Construction Machinery Co ( ($JP:6305) ). Hitachi Construction Machinery has disclosed the progress of ...

Hitachi Construction Machinery Advances Large-Scale Share Buyback Program

HUTCHMED stock soared on Thursday after the company announced a new licensing deal with GlaxoSmithKline.


HUTCHMED Stock (HCM) Rallies Over 15% on a Major Licensing Deal

HUTCHMED (China) ( ($HK:0013) ) has issued an update. HUTCHMED has signed an exclusive development and licensing agreement with a GSK subsidiary fo...

HUTCHMED Licenses First-in-Class KRAS-EGFR Cancer Therapy to GSK in US$1.3 Billion Deal

Citi analyst Ephrem Ravi maintained a Buy rating on Holcim today and set a price target of CHF83.00. According to TipRanks, Ravi is a 5-star analys...

Citi Sticks to Its Buy Rating for Holcim (0QKY)

Bernstein analyst Pujarini Ghosh reiterated a Buy rating on Holcim today and set a price target of CHF90.00. According to TipRanks, Ghosh is a 2-st...

Holcim (0QKY) Receives a Buy from Bernstein

CICC analyst maintained a Buy rating on HUTCHMED (China) yesterday and set a price target of HK$26.00. The company’s shares opened today at HK$20.0...

CICC Sticks to Its Buy Rating for HUTCHMED (China)  (HCM)

Hitachi Construction Machinery Co ( ($JP:6305) ) has issued an announcement. Hitachi Construction Machinery Co., Ltd., a leading Japanese manufactu...

Hitachi Construction Machinery Launches ¥34 Billion Share Buyback to Offset Hitachi Stake Sale

An update from Hitachi Construction Machinery Co ( ($JP:6305) ) is now available. Hitachi Construction Machinery announced that Hitachi, Ltd., its ...

Hitachi Construction Machinery to End Hitachi’s Shareholding as Ownership Base Widens

In a report released on August 14, from CICC maintained a Buy rating on China Mobile, with a price target of HK$102.00. In a report released on Aug...

CICC Sticks to Its Buy Rating for China Mobile (0941)

In a report released on August 14, from Citic Securities maintained a Buy rating on HUTCHMED (China) , with a price target of HK$36.00. The company...

Citic Securities Sticks to Their Buy Rating for HUTCHMED (China)  (HCM)

In a report released yesterday, from CLSA maintained a Buy rating on China Mobile, with a price target of HK$86.00. Currently, the analyst consensu...

China Mobile (0941) Receives a Buy from CLSA

In a report released on August 5, from CICC maintained a Buy rating on HUTCHMED (China) , with a price target of HK$23.80. The company’s shares clo...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HCM	$14.09	-0.14%	150.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HCM	$14.09	-0.1%	150.50K
3
4
5
6

HCM

Get HUTCHMED (China) Limited Data in Excel

Get HUTCHMED (China) Limited Data in Excel